Login to Your Account



Zelluna harvests novel T-cell receptors from cancer vaccine responders

By Cormac Sheridan
Staff Writer

Friday, December 1, 2017

DUBLIN – Zelluna Immunotherapy AS is the latest contender to throw its hat into the immuno-oncology ring, but the Oslo, Norway-based startup can draw on several decades' worth of clinical research in its effort to build a pipeline of cell and biologic therapies based on proprietary T-cell receptors (TCRs) against important tumor antigens.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription